Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
- 20 July 2002
- journal article
- review article
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 6 (4) , 493-500
- https://doi.org/10.1016/s1367-5931(02)00343-5
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Chemosensitization of Pancreatic Cancer by Inhibition of the 26S ProteasomeJournal of Surgical Research, 2001
- 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancerJournal of Cellular Biochemistry, 2001
- Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibitionLeukemia, 2000
- Why Does Threonine, and Not Serine, Function as the Active Site Nucleophile in Proteasomes?Journal of Biological Chemistry, 2000
- Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1Proceedings of the National Academy of Sciences, 1998
- Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid CellsBlood, 1998
- Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acidsBioorganic & Medicinal Chemistry Letters, 1998
- Structure of 20S proteasome from yeast at 2.4Å resolutionNature, 1997
- Crystal Structure of the 20 S Proteasome from the Archaeon T. acidophilum at 3.4 Å ResolutionScience, 1995
- Catalytic Mechanism of the 20S Proteasome of Thermoplasma acidophilum Revealed by X-ray CrystallographyCold Spring Harbor Symposia on Quantitative Biology, 1995